Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Post by rocko65on Mar 03, 2022 9:00pm
320 Views
Post# 34481548

good recap mugs

good recap mugs$67mil in cash, seemed promising to me also other than the $1 mil in rev. 40 contracts or so signed, most getting reimbursed around $12500, they charge $8000 or so bumped up from $7K ish. interesting new options already in use in europe lets the doctor treat the surrounding muscle if need be as sometimes it may spread. is at the fda for approval for that 3-6 months before being available in the US. geographically spreading out in the US reducing travel time for clients and helping with their reimbursement strategy. also pipeline as far as what i could understand equals the number of of contracts they currently have. Asia starting to be in play again somewhat. also he mentioned that the constriction in the hospitals caused by lack anastesiologists. time will tell and need to show growth now and execution. I still believe in Arun . oh also they have a deal with a veteren hospital with an install. he was mentioning that they receive 20K per procedure. doesnt help that the market sucks but hopefully they can continue to grow as the technology seems compelling.
<< Previous
Bullboard Posts
Next >>